KEZAR LIFE SCIENCES, INC.
4000 Shoreline Court, Suite 300
South San Francisco, CA 94080
July 9, 2019
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Donald Field |
| Re: | Kezar Life Sciences, Inc. |
Registration Statement onForm S-3 |
File No. 333-232542 |
Acceleration Request |
| Requested Date: | Thursday, July 11, 2019 |
| Requested Time: | 4:00 P.M. Eastern Daylight Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement onForm S-3 (File No. 333-232542) (the “Registration Statement”) to become effective on Thursday, July 11, 2019, at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”). This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP, counsel to the Registrant, confirming this request. The Registrant hereby authorizes each of Laura Berezin or Jaime Chase of Cooley LLP to make such request on its behalf.
[Signature page follows]
| Very truly yours, | ||
| Kezar Life Sciences, Inc. | ||
| By: | /s/ Marc Belsky | |
| Marc Belsky | ||
| Chief Financial Officer | ||
| cc: | John Fowler, Kezar Life Sciences, Inc. |
Laura Berezin, Cooley LLP |
Jaime Chase, Cooley LLP |
Robert Phillips, Cooley LLP |
